{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:01:26Z","timestamp":1794744086992,"version":"4.9.1"},"reference-count":175,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Multiple myeloma (MM) is a cancerous condition characterized by the proliferation of plasma cells within the hematopoietic marrow, resulting in multiple osteolytic lesions. MM patients typically experience bone pain, kidney damage, fatigue due to anemia, and infections. Historically, MM was an incurable disease with a life expectancy of around three years after diagnosis. However, over the past two decades, the development of novel therapeutics has significantly improved patient outcomes, including response to treatment, remission duration, quality of life, and overall survival. These advancements include thalidomide and its derivatives, lenalidomide and pomalidomide, which exhibit diverse mechanisms of action against the plasma cell clone. Additionally, proteasome inhibitors such as bortezomib, ixazomib, and carfilzomib disrupt protein degradation, proving specifically toxic to cancerous plasma cells. Recent advancements also involve monoclonal antibodies targeting surface antigens, such as elotuzumab (anti-CS1) and daratumumab (anti-CD38), bispecific t-cell engagers such as teclistamab (anti-BCMA\/CD3) and Chimeric antigen receptor T (CAR-T)-based strategies, with a growing focus on drugs that exhibit increasingly targeted action against neoplastic plasma cells and relevant effects on the tumor microenvironment.<\/jats:p>","DOI":"10.3390\/biomedicines11072087","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T01:27:32Z","timestamp":1690248452000},"page":"2087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-9698","authenticated-orcid":false,"given":"Antonio G.","family":"Solimando","sequence":"first","affiliation":[{"name":"Unit of Internal Medicine and Clinical Oncology \u201cG. Baccelli\u201d, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0917-4173","authenticated-orcid":false,"given":"Markus","family":"Krebs","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Mainfranken, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Department of Urology and Pediatric Urology, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-2601","authenticated-orcid":false,"given":"Vanessa","family":"Desantis","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area, Pharmacology Section, University of Bari Aldo Moro Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatello","family":"Marziliano","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine and Clinical Oncology \u201cG. Baccelli\u201d, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid Catalina","family":"Caradonna","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area, Pharmacology Section, University of Bari Aldo Moro Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"Morizio","sequence":"additional","affiliation":[{"name":"Orthopedics and Traumatology Unit ASL BA-Ospedale della Murgia \u201cFabio Perinei\u201d, 70022 Altamura, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Argentiero","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-0436","authenticated-orcid":false,"given":"Endrit","family":"Shahini","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, National Institute of Gastroenterology\u2014IRCCS \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1154-0964","authenticated-orcid":false,"given":"Max","family":"Bittrich","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(15)00094-0","article-title":"Ionising Radiation and Risk of Death from Leukaemia and Lymphoma in Radiation-Monitored Workers (INWORKS): An International Cohort Study","volume":"2","author":"Leuraud","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding Multiple Myeloma Pathogenesis in the Bone Marrow to Identify New Therapeutic Targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple Myeloma: Evolving Genetic Events and Host Interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_7","first-page":"112","article-title":"CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement","volume":"25","author":"Solimando","year":"2019","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3324\/haematol.2019.223024","article-title":"RAL GTPases Mediate Multiple Myeloma Cell Survival and Are Activated Independently of Oncogenic RAS","volume":"105","author":"Seibold","year":"2019","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic Abnormalities and Survival in Multiple Myeloma: The Experience of the Intergroupe Francophone Du My\u00e9lome","volume":"109","author":"Attal","year":"2007","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Da Vi\u00e0, M.C., Cicco, S., Leone, P., Di Lernia, G., Giannico, D., Desantis, V., Frassanito, M.A., Morizio, A., and Delgado Tascon, J. (2019). High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J. Clin. Med., 8.","DOI":"10.20944\/preprints201906.0145.v1"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Krebs, M., Bittrich, M., and Einsele, H. (2022). The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma. J. Clin. Med., 11.","DOI":"10.3390\/jcm11185461"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2012-06-430645","article-title":"Darwinian Evolution and Tiding Clones in Multiple Myeloma","volume":"120","author":"Bahlis","year":"2012","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00277-018-3293-x","article-title":"Rhu-Epo down-Regulates pro-Tumorigenic Activity of Cancer-Associated Fibroblasts in Multiple Myeloma","volume":"97","author":"Desantis","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/leu.2017.287","article-title":"JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma","volume":"32","author":"Solimando","year":"2018","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3324\/haematol.2019.239913","article-title":"Halting the Vicious Cycle within the Multiple Myeloma Ecosystem: Blocking JAM-A on Bone Marrow Endothelial Cells Restores the Angiogenic Homeostasis and Suppresses Tumor Progression","volume":"106","author":"Solimando","year":"2020","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Argentiero, A., Solimando, A.G., Brunetti, O., Calabrese, A., Pantano, F., Iuliani, M., Santini, D., Silvestris, N., and Vacca, A. (2019). Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. Cancers, 11.","DOI":"10.20944\/preprints201908.0088.v1"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Melaccio, A., Vacca, A., and Ria, R. (2022). The Bone Marrow Niche Landscape: A Journey through Aging, Extrinsic and Intrinsic Stressors in the Haemopoietic Milieu. J. Cancer Metastasis Treat., 8.","DOI":"10.20517\/2394-4722.2021.166"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Leich, E., Wei\u00dfbach, S., Klein, H.-U., Grieb, T., Pischimarov, J., St\u00fchmer, T., Chatterjee, M., Steinbrunn, T., Langer, C., and Eilers, M. (2013). Multiple Myeloma Is Affected by Multiple and Heterogeneous Somatic Mutations in Adhesion- and Receptor Tyrosine Kinase Signaling Molecules. Blood Cancer J., 3.","DOI":"10.1038\/bcj.2012.47"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Antonio, G., Oronzo, B., Vito, L., Angela, C., Antonel-la, A., Roberto, C., Giovanni, S.A., and Antonella, L. (2020). Immune System and Bone Microenvironment: Rationale for Targeted Cancer Therapies. Oncotarget, 11.","DOI":"10.18632\/oncotarget.27439"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20563","DOI":"10.18632\/oncotarget.25003","article-title":"Inhibition of MTOR Complex 2 Restrains Tumor Angiogenesis in Multiple Myeloma","volume":"9","author":"Lamanuzzi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Leone, P., Di Lernia, G., Solimando, A.G., Cicco, S., Saltarella, I., Lamanuzzi, A., Ria, R., Frassanito, M.A., Ponzoni, M., and Ditonno, P. (2019). Bone Marrow Endothelial Cells Sustain a Tumor-Specific CD8+ T Cell Subset with Suppressive Function in Myeloma Patients. Oncoimmunology, 8.","DOI":"10.1080\/2162402X.2018.1486949"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of Myeloma Bone Disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A.G., and Baradaran, B. (2021). Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040373"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Annese, T., Tamma, R., Ingravallo, G., Maiorano, E., Vacca, A., Specchia, G., and Ribatti, D. (2020). New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers, 12.","DOI":"10.20944\/preprints202007.0168.v1"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Leone, P., Solimando, A.G., Malerba, E., Fasano, R., Buonavoglia, A., Pappagallo, F., De Re, V., Argentiero, A., Silvestris, N., and Vacca, A. (2020). Actors on the Scene: Immune Cells in the Myeloma Niche. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.599098"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rao, L., Giannico, D., Leone, P., Solimando, A.G., Maiorano, E., Caporusso, C., Duda, L., Tamma, R., Mallamaci, R., and Susca, N. (2020). HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12010173"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The Multiple Myeloma Microenvironment Is Defined by an Inflammatory Stromal Cell Landscape","volume":"22","author":"Kellermayer","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous Immunoglobulins in Patients with Multiple Myeloma and Secondary Hypogammaglobulinemia: A Randomized Trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., and Racanelli, V. (2022). Drug Resistance in Multiple Myeloma: Soldiers and Weapons in the Bone Marrow Niche. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.973836"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous Haematopoietic Stem-Cell Transplantation versus Bortezomib\u2013Melphalan\u2013Prednisone, with or without Bortezomib\u2013Lenalidomide\u2013Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02\/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ria, R., Reale, A., Solimando, A.G., Mangialardi, G., Moschetta, M., Gelao, L., Iodice, G., and Vacca, A. (2012). Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma. Stem Cells Int., 2012.","DOI":"10.1155\/2012\/607260"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal Gammopathy of Undetermined Significance (MGUS) Consistently Precedes Multiple Myeloma: A Prospective Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A Monoclonal Gammopathy Precedes Multiple Myeloma in Most Patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and Survival of Myeloma Patients Diagnosed 2008-2015. Real-World Data on 4904 Patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma Bone Disease: Pathophysiology and Management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of Smoldering Multiple Myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Asymptomatic Myeloma at High Risk for Progression to Symptomatic Disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering (Asymptomatic) Multiple Myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum Free Light Chain Ratio as a Biomarker for High-Risk Smoldering Multiple Myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The Prognostic Importance of the Presence of More than One Focal Lesion in Spine MRI of Patients with Asymptomatic (Smoldering) Multiple Myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for Diagnosis, Staging, Risk Stratification and Response Assessment of Multiple Myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 Patients With Newly Diagnosed Multiple Myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group Guidelines for Serum-Free Light Chain Analysis in Multiple Myeloma and Related Disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.beha.2007.08.005","article-title":"Role of Genetics in Prognostication in Myeloma","volume":"20","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016","volume":"14","author":"Anderson","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.2010.32.5449","article-title":"Advances in Imaging and the Management of Myeloma Bone Disease","volume":"29","author":"Terpos","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International Myeloma Working Group Consensus Statement and Guidelines Regarding the Current Role of Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjh.12820","article-title":"Magnetic Resonance Imaging Pattern of Bone Marrow Involvement as a New Predictive Parameter of Disease Progression in Newly Diagnosed Patients with Multiple Myeloma Eligible for Autologous Stem Cell Transplantation","volume":"165","author":"Song","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic Implications of Serial 18-Fluoro-Deoxyglucose Emission Tomography in Multiple Myeloma Treated with Total Therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/RLU.0000000000000902","article-title":"Role of FDG-PET\/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET\/CT Findings With Clinical Outcome","volume":"41","author":"Tirumani","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Siontis, B., Kumar, S., Dispenzieri, A., Drake, M.T., Lacy, M.Q., Buadi, F., Dingli, D., Kapoor, P., Gonsalves, W., and Gertz, M.A. (2015). Positron Emission Tomography-Computed Tomography in the Diagnostic Evaluation of Smoldering Multiple Myeloma: Identification of Patients Needing Therapy. Blood Cancer J., 5.","DOI":"10.1038\/bcj.2015.87"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT Focal, but Not Osteolytic, Lesions Predict the Progression of Smoldering Myeloma to Active Disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic Relevance of 18-F FDG PET\/CT in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A Prospective Comparison of 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography, Magnetic Resonance Imaging and Whole-Body Planar Radiographs in the Assessment of Bone Disease in Newly Diagnosed Multiple Myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation Criteria for FDG PET\/CT in Multiple Myeloma (IMPeTUs): Final Results. IMPeTUs (Italian Myeloma Criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A Clinical Staging System for Multiple Myeloma Correlation of Measured Myeloma Cell Mass with Presenting Clinical Features, Response to Treatment, and Survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical Implications of t(11;14)(Q13;Q32), t(4;14)(P16.3;Q32), and -17p13 in Myeloma Patients Treated with High-Dose Therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/leu.2009.160","article-title":"The Molecular Characterization and Clinical Management of Multiple Myeloma in the Post-Genome Era","volume":"23","author":"Zhou","year":"2009","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A High-Risk, Double-Hit, Group of Newly Diagnosed Myeloma Identified by Genomic Analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant Global Methylation Patterns Affect the Molecular Pathogenesis and Prognosis of Multiple Myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric Assessment in Multiple Myeloma Patients: Validation of the International Myeloma Working Group (IMWG) Score and Comparison with Other Common Comorbidity Scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric Assessment Predicts Survival and Toxicities in Elderly Myeloma Patients: An International Myeloma Working Group Report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/cncr.32060","article-title":"Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?","volume":"125","author":"Mina","year":"2019","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib Induction, Consolidation, and Maintenance with or without Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Pre-Planned Cytogenetic Subgroup Analysis of the Randomised, Phase 2 FORTE Trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Bazarbachi, A.H., Al Hamed, R., Malard, F., Bazarbachi, A., Harousseau, J.-L., and Mohty, M. (2022). Induction Therapy Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma: An Update. Blood Cancer J., 12.","DOI":"10.1038\/s41408-022-00645-1"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab for Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma (CASSIOPEIA): Health-Related Quality of Life Outcomes of a Randomised, Open-Label, Phase 3 Trial","volume":"7","author":"Roussel","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood.2020006298","article-title":"Daratumumab in Transplant Regimens for Myeloma?","volume":"136","author":"Harousseau","year":"2020","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bmt.2015.322","article-title":"Upfront Plerixafor plus G-CSF versus Cyclophosphamide plus G-CSF for Stem Cell Mobilization in Multiple Myeloma: Efficacy and Cost Analysis Study","volume":"51","author":"Afifi","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline Therapy of Multiple Myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65\/GMMG-HD4 Trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Cavo, M., Goldschmidt, H., Rosinol, L., Pantani, L., Zweegman, S., Salwender, H.J., Lahuerta, J.J., Lokhorst, H.M., Petrucci, M.T., and Blau, I. (2018). Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. Blood, 132.","DOI":"10.1182\/blood-2018-99-112899"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Cavo, M., Beksac, M., Dimopoulos, M.A., Pantani, L., Gay, F., H\u00e1jek, R., Testoni, N., Mellqvist, U.-H., Patriarca, F., and Montefusco, V. (2016). Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02\/HO95 MM Trial). Blood, 128.","DOI":"10.1182\/blood.V128.22.673.673"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-Thalidomide-Dexamethasone Is Superior to Thalidomide-Dexamethasone as Consolidation Therapy after Autologous Hematopoietic Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Dexamethasone as Induction Therapy before, and Consolidation Therapy after, Double Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Randomised Phase 3 Study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Gay, F., Cerrato, C., Petrucci, M.T., Zambello, R., Gamberi, B., Ballanti, S., Omed\u00e8, P., Palmieri, S., Troia, R., and Spada, S. (2019). Efficacy of Carfilzomib Lenalidomide Dexamethasone (KRd) with or without Transplantation in Newly Diagnosed Myeloma According to Risk Status: Results from the FORTE Trial. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.8002"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-Year Median Time to Progression with Thalidomide for Smoldering Myeloma: Partial Response Identifies Subset Requiring Earlier Salvage Therapy for Symptomatic Disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous Transplantation and Maintenance Therapy in Multiple Myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus Lenalidomide versus Autologous Transplantation, Followed by Lenalidomide plus Prednisone versus Lenalidomide Maintenance, in Patients with Multiple Myeloma: A Randomised, Multicentre, Phase 3 Trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-136907","article-title":"Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial","volume":"136","author":"Gay","year":"2020","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral Ixazomib Maintenance Following Autologous Stem Cell Transplantation (TOURMALINE-MM3): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with Daratumumab or Observation Following Treatment with Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab and Autologous Stem-Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma (CASSIOPEIA): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1182\/blood-2011-03-339945","article-title":"Long-Term Follow-up of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma","volume":"117","author":"Giaccone","year":"2011","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3324\/haematol.2017.174573","article-title":"From Transplant to Novel Cellular Therapies in Multiple Myeloma: European Myeloma Network Guidelines and Future Perspectives","volume":"103","author":"Gay","year":"2018","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/Schedule-Adjusted Rd-R vs Continuous Rd for Elderly, Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral Melphalan, Prednisone, and Thalidomide in Elderly Patients with Multiple Myeloma: Updated Results of a Randomized Controlled Trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral Melphalan and Prednisone Chemotherapy plus Thalidomide Compared with Melphalan and Prednisone Alone in Elderly Patients with Multiple Myeloma: Randomised Controlled Trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and Prednisone plus Thalidomide versus Melphalan and Prednisone Alone or Reduced-Intensity Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma (IFM 99\u201306): A Randomised Trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01\/01 Trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and Prednisone versus Melphalan, Prednisone and Thalidomide for Elderly and\/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for Previously Untreated Elderly Patients with Multiple Myeloma: Meta-Analysis of 1685 Individual Patient Data from 6 Randomized Clinical Trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma","volume":"31","author":"Schlag","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma","volume":"359","author":"Schlag","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-Label, Phase 3 Trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","article-title":"Lenalidomide in Combination with Dexamethasone at First Relapse in Comparison with Its Use as Later Salvage Therapy in Relapsed or Refractory Multiple Myeloma","volume":"82","author":"Stadtmauer","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus Dexamethasone Is More Effective than Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Prior Thalidomide Exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus High-Dose Dexamethasone versus Lenalidomide plus Low-Dose Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma: An Open-Label Randomised Controlled Trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone Alone in Patients with Newly Diagnosed Myeloma without Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): A Randomised, Open-Label, Phase 3 Trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Durie, B.G.M., Hoering, A., Sexton, R., Abidi, M.H., Epstein, J., Rajkumar, S.V., Dispenzieri, A., Kahanic, S.P., Thakuri, M.C., and Reu, F.J. (2020). Longer Term Follow-up of the Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT). Blood Cancer J., 10.","DOI":"10.1038\/s41408-020-0311-8"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma and the Impact of Daratumumab in MAIA and ALCYONE","volume":"139","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","article-title":"Maintenance Therapy with Bortezomib plus Thalidomide or Bortezomib plus Prednisone in Elderly Multiple Myeloma Patients Included in the GEM2005MAS65 Trial","volume":"120","author":"Mateos","year":"2012","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Bonello, F., Boccadoro, M., and Larocca, A. (2020). Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients. Cancers, 12.","DOI":"10.3390\/cancers12113106"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino, M., Larocca, A., Offidani, M., Liberati, A.M., Gaidano, G., Petrucci, M.T., Derudas, D., Capra, A., Zambello, R., and Cascavilla, N. (2021). Octogenarian Newly Diagnosed Multiple Myeloma Patients without Geriatric Impairments: The Role of Age >80 in the IMWG Frailty Score. Blood Cancer J., 11.","DOI":"10.1038\/s41408-021-00464-w"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Facon, T., Leleu, X., and Manier, S. (2023). How I Treat Multiple Myeloma in the Geriatric Patient. Blood, in press.","DOI":"10.1182\/blood.2022017635"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S2666-7568(22)00218-5","article-title":"Defining FiTNEss for Treatment for Multiple Myeloma","volume":"3","author":"Cook","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-Term Follow-up on Overall Survival from the MM-009 and MM-010 Phase III Trials of Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3816\/CLML.2010.n.120","article-title":"Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone","volume":"11","author":"Dimopoulos","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","article-title":"Bortezomib Is Associated with Better Health-Related Quality of Life than High-Dose Dexamethasone in Patients with Relapsed Multiple Myeloma: Results from the APEX Study","volume":"143","author":"Lee","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","article-title":"Safety and Efficacy of Bortezomib in High-Risk and Elderly Patients with Relapsed Multiple Myeloma","volume":"137","author":"Richardson","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended Follow-up of a Phase 3 Trial in Relapsed Multiple Myeloma: Final Time-to-Event Results of the APEX Trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Di Lernia, G., Leone, P., Solimando, A.G., Buonavoglia, A., Saltarella, I., Ria, R., Ditonno, P., Silvestris, N., Crudele, L., and Vacca, A. (2020). Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020552"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"13366","DOI":"10.18632\/oncotarget.24351","article-title":"Targeting Angiogenesis in Multiple Myeloma by the VEGF and HGF Blocking DARPin\u00ae Protein MP0250: A Preclinical Study","volume":"9","author":"Rao","year":"2018","journal-title":"Oncotarget"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Desantis, V., Saltarella, I., Lamanuzzi, A., Melaccio, A., Solimando, A.G., Mariggi\u00f2, M.A., Racanelli, V., Paradiso, A., Vacca, A., and Frassanito, M.A. (2020). MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093084"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Desantis, V., Solimando, A.G., Saltarella, I., Sacco, A., Giustini, V., Bento, M., Lamanuzzi, A., Melaccio, A., Frassanito, M.A., and Paradiso, A. (2021). MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease. Cancers, 13.","DOI":"10.3390\/cancers13153650"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Dimopoulos, M.A., Lonial, S., White, D., Moreau, P., Weisel, K., San-Miguel, J., Shpilberg, O., Grosicki, S., \u0160pi\u010dka, I., and Walter-Croneck, A. (2020). Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results from the Phase 3 Randomized ELOQUENT-2 Study. Blood Cancer J., 10.","DOI":"10.1038\/s41408-020-00357-4"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab Monotherapy in Patients with Treatment-Refractory Multiple Myeloma (SIRIUS): An Open-Label, Randomised, Phase 2 Trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus Lenalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma: Extended Follow-up of POLLUX, a Randomized, Open-Label, Phase 3 Study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and Dexamethasone versus Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open-Label, Multicentre Study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or Bortezomib in Relapsed or Refractory Multiple Myeloma (ENDEAVOR): An Interim Overall Survival Analysis of an Open-Label, Randomised, Phase 3 Trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma (IKEMA): A Multicentre, Open-Label, Randomised Phase 3 Trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Usmani, S.Z., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D.S., Weisel, K., Yang, H., Klippel, Z.K., and Zahlten-Kumeli, A. (2019). Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688). Blood, 134.","DOI":"10.1182\/blood-2019-132629"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus Bortezomib and Dexamethasone versus Placebo plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: A Multicentre, Randomised, Double-Blind Phase 3 Trial","volume":"15","author":"Hungria","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus Low-Dose Dexamethasone versus High-Dose Dexamethasone Alone for Patients with Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor\u2013Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International Uniform Response Criteria for Multiple Myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents","volume":"28","author":"Giralt","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete Response Correlates with Long-Term Progression-Free and Overall Survival in Elderly Myeloma Treated with Novel Agents: Analysis of 1175 Patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete Response Correlates with Long-Term Survival and Progression-Free Survival in High-Dose Therapy in Multiple Myeloma","volume":"92","author":"Liu","year":"2007","journal-title":"Haematologica"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A Phase 1\/2 Study of Carfilzomib in Combination with Lenalidomide and Low-Dose Dexamethasone as a Frontline Treatment for Multiple Myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-Risk Cytogenetics and Persistent Minimal Residual Disease by Multiparameter Flow Cytometry Predict Unsustained Complete Response after Autologous Stem Cell Transplantation in Multiple Myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter Flow Cytometric Remission Is the Most Relevant Prognostic Factor for Multiple Myeloma Patients Who Undergo Autologous Stem Cell Transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic Value of Deep Sequencing Method for Minimal Residual Disease Detection in Multiple Myeloma","volume":"123","author":"Lahuerta","year":"2014","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical Evaluation of ASO RQ-PCR for Minimal Residual Disease Evaluation in Multiple Myeloma. A Comparative Analysis with Flow Cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the Diagnosis and Management of Multiple Myeloma and Other Plasma Cell Disorders: A Consensus Statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2022007052","article-title":"Utility of PET\/CT in Assessing Early Treatment Response in Patients with Newly Diagnosed Multiple Myeloma","volume":"6","author":"Charalampous","year":"2022","journal-title":"Blood Adv."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Jelinek, T., Paiva, B., and Hajek, R. (2018). Update on PD-1\/PD-L1 Inhibitors in Multiple Myeloma. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02431"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Crudele, L., Leone, P., Argentiero, A., Guarascio, M., Silvestris, N., Vacca, A., and Racanelli, V. (2020). Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093054"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Argentiero, A., Solimando, A.G., Ungaro, V., Laforgia, M., Strippoli, S., Pinto, D., Negri, A., Ferraiuolo, S., Zito, A., and Guida, M. (2020). Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.583781"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/7\/2087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:18:11Z","timestamp":1760127491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/7\/2087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":175,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["biomedicines11072087"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11072087","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]}}}